

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the **ABSTRACT TEMPLATE** online, for Biomed 2025 Company Presentations  
All items marked with an \* are mandatory to complete  
The maximum number of words for this abstract is 400  
Please be sure to complete the following:

1E Therapeutics Ltd \* [www.1etx.com](http://www.1etx.com) \*

Gur Roshwalb, MD

Select a **CATEGORY**: Biotech/Pharma \*  
(Delete categories you are not selecting)

Select up to two **SESSIONS** per abstract from the list below \*  
(Delete sessions you are not selecting)

- **Redefining the fight against Cancer: New Targets and Novel Therapeutic Modalities**

You may delete the section instructions, leaving only the **bolded bullet title**  
Answers below should not exceed 60 words per question:

- **Executive Summary** – 1E Therapeutics is advancing a novel platform for RNA interference focusing on allele specific knockdown
- **Core Technology** – This novel mode of RNA interference is single base pair specific in its targeting capabilities allowing for allele and isoform specific knockdown
- **Product Profile/Pipeline** Company is preclinical focusing on targets in hematology, immunology and neurodegeneration. We are targeting opening INDs in 2027 and clinical POC in 2028.
- **Business Strategy Briefly** – by developing new therapies for our lead indications.
- **What's Next?** We are focusing on lead optimization, to be followed by in vivo POC and then pre-clinical toxicology studies.